Please enable JavaScript to continue using this application.

Compare $ALEC vs $KROS | Chartloom

Compare

$ALEC vs $KROS

Alector Inc · Keros Therapeutics Inc

ALEC

Alector Inc

KROS

Keros Therapeutics Inc

Compare $ALEC vs $KROS

Comparing Alector Inc and Keros Therapeutics Inc

ALECAlector Inc

KROSKeros Therapeutics Inc

ALECAlector Inc

Market cap

$231M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

34.29x

Rev growth (TTM)

-82.9%

YTD performance

35.9%

52W performance

-32.5%

FCF yield

-68.6%

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALEC

KROS

Detailed metrics comparison

ALEC

Alector Inc

KROS

Keros Therapeutics Inc

Market Cap

ALEC$231M

KROS$236M

Enterprise Value

ALEC$181M

KROS$-21M

Price

ALEC$2.08

KROS$11.95

P/E Ratio

ALECN/A

KROSN/A

P/S Ratio

ALEC16.66x

KROS15.75x

EV/Sales

ALEC13.05x

KROS-1.41x

EV/EBITDA

ALEC3.60x

KROS-0.47x

P/B Ratio

ALEC19.47x

KROS0.86x

P/FCF Ratio

ALECN/A

KROSN/A

EV/FCF

ALEC-1.14x

KROS0.44x

PEG Ratio

ALECN/A

KROSN/A

Forward P/E (NTM)

ALECN/A

KROSN/A

Forward P/S (NTM)

ALEC34.29x

KROSN/A

Revenue (TTM)

ALEC$14M

KROS$15M

Revenue Growth (YoY)

ALEC-82.9%

KROS-93.6%

Forward Rev Growth

ALEC281.0%

KROS-96.3%

Gross Margin (TTM)

ALEC0.0%

KROS0.0%

Operating Margin (TTM)

ALEC0.0%

KROS0.0%

EBITDA Margin (TTM)

ALEC-879.7%

KROS-665.2%

Net Margin (TTM)

ALEC-850.1%

KROS-553.9%

FCF Margin (TTM)

ALEC-1142.6%

KROS-322.9%

Net Income (TTM)

ALEC$-118M

KROS$-83M

FCF (TTM)

ALEC$-158M

KROS$-48M

EPS (TTM)

ALEC-$1.06

KROS-$4.20

ROE (TTM)

ALEC-29517.0%

KROS-2140.0%

ROA (TTM)

ALEC-4400.0%

KROS-1979.0%

ROIC (TTM)

ALEC-24053.0%

KROS-2140.0%

Cash

ALEC$60M

KROS$258M

Debt

ALEC$10M

KROS$0

Net Cash/Debt

ALEC$50M

KROS$258M

Current Ratio (TTM)

ALEC5.26x

KROS21.96x

Quick Ratio (TTM)

ALEC5.05x

KROS21.53x

Debt/Equity (TTM)

ALEC0.94x

KROS0.00x

Debt/Assets (TTM)

ALEC0.0%

KROS0.0%

Interest Coverage (TTM)

ALECN/A

KROSN/A

Net Debt/EBITDA (TTM)

ALEC0.00x

KROS0.00x

Beta

ALEC0.65

KROS1.20

52W Performance

ALEC-32.5%

KROS-25.1%

YTD Performance

ALEC35.9%

KROS-35.5%

% from 52W High

ALEC-38.8%

KROS-47.0%

% from 52W Low

ALEC90.8%

KROS23.3%

Asset Turnover (TTM)

ALEC0.05x

KROS0.06x

FCF Yield (TTM)

ALEC-68.6%

KROS-20.5%

Earnings Yield (TTM)

ALEC-51.0%

KROS-35.2%

Dividend Yield (TTM)

ALECN/A

KROSN/A

Rule of 40

ALEC-1,225.5

KROS-416.5

EV/GP/RG

ALECN/A

KROSN/A

Ticker research

View ALEC research View KROS research

Metric	ALEC Alector Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$231M	$236M
Enterprise Value	$181M	$-21M
Price	$2.08	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	16.66x	15.75x
EV/Sales	13.05x	-1.41x
EV/EBITDA	3.60x	-0.47x
P/B Ratio	19.47x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.14x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	34.29x	N/A
Revenue & Growth
Revenue (TTM)	$14M	$15M
Revenue Growth (YoY)	-82.9%	-93.6%
Forward Rev Growth	281.0%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-879.7%	-665.2%
Net Margin (TTM)	-850.1%	-553.9%
FCF Margin (TTM)	-1142.6%	-322.9%
Net Income (TTM)	$-118M	$-83M
FCF (TTM)	$-158M	$-48M
EPS (TTM)	-$1.06	-$4.20
ROE (TTM)	-29517.0%	-2140.0%
ROA (TTM)	-4400.0%	-1979.0%
ROIC (TTM)	-24053.0%	-2140.0%
Financial Health
Cash	$60M	$258M
Debt	$10M	$0
Net Cash/Debt	$50M	$258M
Current Ratio (TTM)	5.26x	21.96x
Quick Ratio (TTM)	5.05x	21.53x
Debt/Equity (TTM)	0.94x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	1.20
52W Performance	-32.5%	-25.1%
YTD Performance	35.9%	-35.5%
% from 52W High	-38.8%	-47.0%
% from 52W Low	90.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.06x
FCF Yield (TTM)	-68.6%	-20.5%
Earnings Yield (TTM)	-51.0%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,225.5	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View ALEC research	View KROS research

Valuation

P/S Ratio

KROS

15.75x

ALEC

16.66x

EV/FCF

ALEC

-1.14x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

ALEC

-82.9%

KROS

-93.6%

Forward Revenue Growth

ALEC

281.0%

KROS

-96.3%

Profitability & performance

Gross Margin

ALEC

0.0%

KROS

0.0%

ROE

KROS

-2140.0%

ALEC

-29517.0%

FCF Yield %

KROS

-20.5%

ALEC

-68.6%

52-Week Performance

KROS

-25.1%

ALEC

-32.5%

Detailed metrics comparison

ALEC

Alector Inc

KROS

Keros Therapeutics Inc

Market Cap

ALEC$231M

KROS$236M

Enterprise Value

ALEC$181M

KROS$-21M

Price

ALEC$2.08

KROS$11.95

P/E Ratio

ALECN/A

KROSN/A

P/S Ratio

ALEC16.66x

KROS15.75x

EV/Sales

ALEC13.05x

KROS-1.41x

EV/EBITDA

ALEC3.60x

KROS-0.47x

P/B Ratio

ALEC19.47x

KROS0.86x

P/FCF Ratio

ALECN/A

KROSN/A

EV/FCF

ALEC-1.14x

KROS0.44x

PEG Ratio

ALECN/A

KROSN/A

Forward P/E (NTM)

ALECN/A

KROSN/A

Forward P/S (NTM)

ALEC34.29x

KROSN/A

Revenue (TTM)

ALEC$14M

KROS$15M

Revenue Growth (YoY)

ALEC-82.9%

KROS-93.6%

Forward Rev Growth

ALEC281.0%

KROS-96.3%

Gross Margin (TTM)

ALEC0.0%

KROS0.0%

Operating Margin (TTM)

ALEC0.0%

KROS0.0%

EBITDA Margin (TTM)

ALEC-879.7%

KROS-665.2%

Net Margin (TTM)

ALEC-850.1%

KROS-553.9%

FCF Margin (TTM)

ALEC-1142.6%

KROS-322.9%

Net Income (TTM)

ALEC$-118M

KROS$-83M

FCF (TTM)

ALEC$-158M

KROS$-48M

EPS (TTM)

ALEC-$1.06

KROS-$4.20

ROE (TTM)

ALEC-29517.0%

KROS-2140.0%

ROA (TTM)

ALEC-4400.0%

KROS-1979.0%

ROIC (TTM)

ALEC-24053.0%

KROS-2140.0%

Cash

ALEC$60M

KROS$258M

Debt

ALEC$10M

KROS$0

Net Cash/Debt

ALEC$50M

KROS$258M

Current Ratio (TTM)

ALEC5.26x

KROS21.96x

Quick Ratio (TTM)

ALEC5.05x

KROS21.53x

Debt/Equity (TTM)

ALEC0.94x

KROS0.00x

Debt/Assets (TTM)

ALEC0.0%

KROS0.0%

Interest Coverage (TTM)

ALECN/A

KROSN/A

Net Debt/EBITDA (TTM)

ALEC0.00x

KROS0.00x

Beta

ALEC0.65

KROS1.20

52W Performance

ALEC-32.5%

KROS-25.1%

YTD Performance

ALEC35.9%

KROS-35.5%

% from 52W High

ALEC-38.8%

KROS-47.0%

% from 52W Low

ALEC90.8%

KROS23.3%

Asset Turnover (TTM)

ALEC0.05x

KROS0.06x

FCF Yield (TTM)

ALEC-68.6%

KROS-20.5%

Earnings Yield (TTM)

ALEC-51.0%

KROS-35.2%

Dividend Yield (TTM)

ALECN/A

KROSN/A

Rule of 40

ALEC-1,225.5

KROS-416.5

EV/GP/RG

ALECN/A

KROSN/A

Ticker research

View ALEC research View KROS research

Metric	ALEC Alector Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$231M	$236M
Enterprise Value	$181M	$-21M
Price	$2.08	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	16.66x	15.75x
EV/Sales	13.05x	-1.41x
EV/EBITDA	3.60x	-0.47x
P/B Ratio	19.47x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.14x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	34.29x	N/A
Revenue & Growth
Revenue (TTM)	$14M	$15M
Revenue Growth (YoY)	-82.9%	-93.6%
Forward Rev Growth	281.0%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-879.7%	-665.2%
Net Margin (TTM)	-850.1%	-553.9%
FCF Margin (TTM)	-1142.6%	-322.9%
Net Income (TTM)	$-118M	$-83M
FCF (TTM)	$-158M	$-48M
EPS (TTM)	-$1.06	-$4.20
ROE (TTM)	-29517.0%	-2140.0%
ROA (TTM)	-4400.0%	-1979.0%
ROIC (TTM)	-24053.0%	-2140.0%
Financial Health
Cash	$60M	$258M
Debt	$10M	$0
Net Cash/Debt	$50M	$258M
Current Ratio (TTM)	5.26x	21.96x
Quick Ratio (TTM)	5.05x	21.53x
Debt/Equity (TTM)	0.94x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	1.20
52W Performance	-32.5%	-25.1%
YTD Performance	35.9%	-35.5%
% from 52W High	-38.8%	-47.0%
% from 52W Low	90.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.06x
FCF Yield (TTM)	-68.6%	-20.5%
Earnings Yield (TTM)	-51.0%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,225.5	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View ALEC research	View KROS research